Reduction in Prevalence of Thrombotic Events in Sickle Cell Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Ameet Patel(Vanderbilt University Medical Center), Adetola A. Kassim(Vanderbilt University), Michael Byrne(Vanderbilt University Medical Center), Brian G. Engelhardt(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Wichai Chinratanalab(VA Tennessee Valley Healthcare System), Katie S. Gatwood(Vanderbilt University Medical Center), Kathryn A. Culos(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Bipin N. Savani(Vanderbilt University Medical Center), Jennifer Green(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), Karina L Wilkerson(Vanderbilt University Medical Center), Stacey Goodman(Texas Oncology)
Cited by 0
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
|The Lancet Oncology|2017|1.1k
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554